The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | SYNCAR-001 in combination with STK-009 in R/R CD19 expressing hematologic malignancies
Matthew Cortese, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares the results of a Phase I study evaluating the safety and efficacy of a novel combination autologous CD19 CAR T-cell therapy (SYNCAR-001) with orthogonal IL-2 (STK-009) in patients with relapsed/refractory (R/R) CD19-expressing hematologic malignancies. This study showed excellent efficacy in marginal zone lymphoma (MZL) and diffuse large B-cell lymphoma (DLBCL), with a unique platform that stabilizes T-cells and allows persistence. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
